Announcement from 2cureX extra general meeting
November 5, 2020
RESOLUTION REGARDING INCENTIVE PROGRAM 2020/2023 FOR CERTAIN MEMBERS OF THE BOARD OF DIRECTORS
It was resolved, in accordance with the shareholder Grith Hagel's proposal, to issue a maximum of 120,000 warrants, which may result in a maximum increase in the Company’s share capital of SEK 12,000. The warrants shall entitle to subscription of new shares in the Company.
The warrants may, with deviation from the shareholders' preferential rights, be subscribed for by the directors Nils Brünner, Camilla Huse Bondesson and Michael Lutz, whereby all directors who have been offered to subscribe for warrants have the right to subscribe for a maximum of 40,000 warrants each, a total of 120,000 warrants if all warrants are subscribed for.
The warrants shall be subscribed for as of 6 November 2020 up to and including 20 November 2020 on a separate subscription list, with a right for the board to extend the subscription period.
The warrants are issued at no consideration.
Each warrant entitles to subscription of one (1) new share in the Company during the period from 1 October 2023 up to an including 31 December 2023 or the earlier date set forth in the terms for the warrants.
The subscription price shall be determined to an amount equal to 110 percent of the volume weighted average price at Nasdaq First North Growth Market during a period of ten trading days following the extra general meeting on 5 November 2020.
The maximum dilution of the incentive program is estimated to be a maximum of approximately 0.80 percent of the total number of shares and votes in the Company (calculated on the number of existing shares the Company), assuming full subscription and exercise of all warrants offered. The maximum dilution of the incentive program plus the other outstanding incentive programs in the Company is estimated to be a maximum of approximately 2.11 percent, assuming full subscription and exercise of all warrants offered and outstanding.
For the full proposal regarding the above resolution at the extra general meeting, please refer to the notice which is available on the Company's website, www.2cureX.com.
For more information about 2cureX, please contact:
Ole Thastrup, CEO
Telefon: +45 22 11 53 99
Telefon: +46 8 121 576 90
2cureX has developed the IndiTreat® (Individual Treatment) test. IndiTreat® establishes thousands of 3D micro-tumors that are similar to the patient’s tumor and identifies the treatment that most effectively kills the patient’s tumor and the treatment to which the patient is resistant. Immediately after the test, the patient can be offered the selected treatment.
IndiTreat® is being clinically validated in clinical studies in colorectal cancer, ovarian cancer, pancreatic cancer and preventive cancer medicine. The clinical programs are conducted at major cancer hospitals in Denmark, Germany, Sweden and United Kingdom.
IndiTreat® is presently being introduced into the European market.
The aspiration is that IndiTreat® becomes a standard Functional Precision Medicine tool for cancer patients.
The company is listed at the Nasdaq First North Growth Market in Stockholm (symbol: "2CUREX").